Impact of sunitinib resistance on clear cell renal cell carcinoma therapeutic sensitivity in vitro

References

• Clark PE. The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy. Kidney Int. 2009;76(9):939–945. doi: 10.1038/ki.2009.296
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM, et al. A randomized trial of Bevacizumab, an anti–vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349(5):427–434. doi: 10.1056/NEJMoa021491
   PubMed Web of Science ®Google Scholar
• Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3(5):391–400. doi: 10.1038/nrd1381
   PubMed Web of Science ®Google Scholar
• Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004;10(2):145–147. doi: 10.1038/nm988
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24(1):16–24. doi: 10.1200/JCO.2005.02.2574
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295(21):2516–2524. doi: 10.1001/jama.295.21.2516
   PubMed Web of Science ®Google Scholar
• Abrams TJ, Lee LB, Murray LJ, et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003;2(5):471–478.
   PubMed Web of Science ®Google Scholar
• Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9(1):327–337.
   PubMed Web of Science ®Google Scholar
• Joosten SC, Hamming L, Soetekouw PM, et al. Resistance to sunitinib in renal cell carcinoma: from molecular mechanisms to predictive markers and future perspectives. Biochim Biophys Acta. 2015;1855(1):1–16. doi: 10.1016/j.bbcan.2014.11.002
   PubMed Web of Science ®Google Scholar
• Graham DK, DeRyckere D, Davies KD, et al. The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. Nat Rev Cancer. 2014;14(12):769–785. doi: 10.1038/nrc3847
   PubMed Web of Science ®Google Scholar
• van der Mijn JC, Broxterman HJ, Knol JC, et al. Sunitinib activates Axl signaling in renal cell cancer. Int J Cancer. 2016;138(12):3002–3010. doi: 10.1002/ijc.30022
   PubMed Web of Science ®Google Scholar
• Yu H, Liu R, Ma B, et al. Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma. Br J Cancer. 2015;113(4):616–625. doi: 10.1038/bjc.2015.237
   PubMed Web of Science ®Google Scholar
• Diaz-Montero CM, Mao FJ, Barnard J, et al. MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model. Br J Cancer. 2016;115(8):920–928. doi: 10.1038/bjc.2016.263
   PubMed Web of Science ®Google Scholar
• Xu L, Chen S, Bergan RC. MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer. Oncogene. 2006;25(21):2987–2998. doi: 10.1038/sj.onc.1209337
   PubMed Web of Science ®Google Scholar
• Nayak Rao S. The role of heat shock proteins in kidney disease. J Transl Int Med. 2016;4(3):114–117. doi: 10.1515/jtim-2016-0034
   PubMedGoogle Scholar
• Lampros M, Vlachos N, Voulgaris S, et al. The role of Hsp27 in chemotherapy resistance. Biomedicines. 2022;10(4):10. doi: 10.3390/biomedicines10040897
   Web of Science ®Google Scholar
• Kumar S, Jiang MS, Adams JL, et al. Pyridinylimidazole compound SB 203580 inhibits the activity but not the activation of p38 mitogen-activated protein kinase. Biochem Biophys Res Commun. 1999;263(3):825–831. doi: 10.1006/bbrc.1999.1454
   PubMed Web of Science ®Google Scholar
• Düzgün ŞA, Yerlikaya A, Zeren S, et al. Differential effects of p38 MAP kinase inhibitors SB203580 and SB202190 on growth and migration of human MDA-MB-231 cancer cell line. Cytotechnology. 2017;69(4):711–724. doi: 10.1007/s10616-017-0079-2
   PubMed Web of Science ®Google Scholar
• Shin SJ, Jeon YK, Cho YM, et al. The association between PD-L1 expression and the clinical outcomes to vascular endothelial growth factor-targeted therapy in patients with metastatic clear cell renal cell carcinoma. Oncology. 2015;20(11):1253–1260. doi: 10.1634/theoncologist.2015-0151
   Google Scholar
• Liu XD, Hoang A, Zhou L, et al. Resistance to antiangiogenic therapy is associated with an immunosuppressive tumor microenvironment in metastatic renal cell carcinoma. Cancer Immunol Res. 2015;3(9):1017–1029. doi: 10.1158/2326-6066.CIR-14-0244
   PubMed Web of Science ®Google Scholar
• Cha JH, Yang WH, Xia W, et al. Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1. Mol Cell. 2018;71(4):606–620.e7. doi: 10.1016/j.molcel.2018.07.030
   PubMed Web of Science ®Google Scholar
• Garige M, Ghosh S, Norris A, et al. PD-L1 mediates IFNγ-regulation of glucose but not of tryptophan metabolism in clear cell renal cell carcinoma. Front Oncol. 2022;12:12. doi: 10.3389/fonc.2022.858379
   Web of Science ®Google Scholar
• Creighton CJ, Morgan M, Gunaratne PH, et al. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499:43–49.
   PubMed Web of Science ®Google Scholar
• Lucarelli G, Ferro M, Battaglia M. Multi-omics approach reveals the secrets of metabolism of clear cell—renal cell carcinoma. Transl Androl Urol. 2016;5(5):801–803. doi: 10.21037/tau.2016.06.12
   PubMed Web of Science ®Google Scholar
• Lucarelli G, Loizzo D, Franzin R, et al. Metabolomic insights into pathophysiological mechanisms and biomarker discovery in clear cell renal cell carcinoma. Expert Rev Mol Diagn. 2019;19(5):397–407. doi: 10.1080/14737159.2019.1607729
   PubMed Web of Science ®Google Scholar
• Deleuze A, Saout J, Dugay F, et al. Immunotherapy in Renal Cell Carcinoma: The Future Is Now. Int J Mol Sci. 2020;21(7):21. doi: 10.3390/ijms21072532
   Web of Science ®Google Scholar
• Huang JJ, Hsieh JJ. The therapeutic landscape of renal cell carcinoma: from the Dark Age to the Golden Age. Semin Nephrol. 2020;40(1):28–41. doi: 10.1016/j.semnephrol.2019.12.004
   PubMed Web of Science ®Google Scholar
• Tegos T, Tegos K, Dimitriadou A, et al. Current and emerging first-line systemic therapies in metastatic clear-cell renal cell carcinoma. J Buon. 2019;24(4):1340–1353.
   PubMed Web of Science ®Google Scholar
• Hack SP, Zhu AX, Wang Y. Augmenting anticancer immunity through combined targeting of angiogenic and PD-1/PD-L1 pathways: challenges and opportunities. Front Immunol. 2020;11:598877. doi: 10.3389/fimmu.2020.598877
   PubMed Web of Science ®Google Scholar
• Yang F, Jove V, Xin H, et al. Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways. Mol Cancer Res. 2010;8(1):35–45. doi: 10.1158/1541-7786.MCR-09-0220
   PubMed Web of Science ®Google Scholar
• Hatakeyama H, Fujiwara T, Sato H, et al. Investigation of metabolomic changes in sunitinib-resistant human renal carcinoma 786-O cells by capillary electrophoresis-time of flight mass spectrometry. Biol Pharm Bull. 2018;41(4):619–627. doi: 10.1248/bpb.b17-00992
   PubMed Web of Science ®Google Scholar
• Sato T, Kawasaki Y, Maekawa M, et al. Metabolomic analysis to elucidate mechanisms of sunitinib resistance in renal cell carcinoma. Metabolites. 2021;11(1):1. doi: 10.3390/metabo11010001
   Web of Science ®Google Scholar
• Trigo Perez JM, Felip E, Brunsvig P, et al. 1576P - Efficacy results of selective AXL inhibitor bemcentinib with pembrolizumab following chemo in patients with NSCLC. Ann Oncol. 2019;30:v649–v650. doi: 10.1093/annonc/mdz260.098
   Web of Science ®Google Scholar
• Choi SK, Kam H, Kim KY, et al. Targeting heat shock protein 27 in cancer: a druggable target for cancer treatment? Cancers (Basel). 2019;11(8):1195.
   PubMed Web of Science ®Google Scholar
• Liu L. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and fc-fusion proteins. J Pharmaceut sci. 2015;104(6):1866–1884. doi: 10.1002/jps.24444
   PubMed Web of Science ®Google Scholar
• Zheng K, Bantog C, Bayer R. The impact of glycosylation on monoclonal antibody conformation and stability. MAbs. 2011;3(6):568–576. doi: 10.4161/mabs.3.6.17922
   PubMed Web of Science ®Google Scholar
• Makhov P, Joshi S, Ghatalia P, et al. Resistance to systemic therapies in clear cell renal cell carcinoma: mechanisms and management strategies. Mol Cancer Ther. 2018;17(7):1355–1364. doi: 10.1158/1535-7163.MCT-17-1299
   PubMed Web of Science ®Google Scholar
• Goto Y, Kurozumi A, Nohata N, et al. The microRNA signature of patients with sunitinib failure: regulation of UHRF1 pathways by microRNA-101 in renal cell carcinoma. Oncotarget. 2016;7(37):59070–59086. doi: 10.18632/oncotarget.10887
   PubMedGoogle Scholar
• Haouala A, Rumpold H, Untergasser G, et al. siRNA-mediated knock-down of P-glycoprotein expression reveals distinct cellular disposition of anticancer tyrosine kinases inhibitors. Drug Metab Lett. 2010;4(2):114–119. doi: 10.2174/187231210791292726
   PubMedGoogle Scholar
• Hu S, Chen Z, Franke R, et al. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res. 2009;15(19):6062–6069. doi: 10.1158/1078-0432.CCR-09-0048
   PubMed Web of Science ®Google Scholar
• Bianchi C, Meregalli C, Bombelli S, et al. The glucose and lipid metabolism reprogramming is grade-dependent in clear cell renal cell carcinoma primary cultures and is targetable to modulate cell viability and proliferation. Oncotarget. 2017;8(69):113502–113515. doi: 10.18632/oncotarget.23056
   PubMedGoogle Scholar
• Bombelli S, Torsello B, De Marco S, et al. 36-kDa annexin A3 isoform negatively modulates lipid storage in clear cell renal cell carcinoma cells. Am J Pathol. 2020;190(11):2317–2326. doi: 10.1016/j.ajpath.2020.08.008
   PubMed Web of Science ®Google Scholar
• Lucarelli G, Rutigliano M, Sallustio F, et al. Integrated multi-omics characterization reveals a distinctive metabolic signature and the role of NDUFA4L2 in promoting angiogenesis, chemoresistance, and mitochondrial dysfunction in clear cell renal cell carcinoma. Aging. 2018;10(12):3957–3985. doi: 10.18632/aging.101685
   PubMedGoogle Scholar
• Ragone R, Sallustio F, Piccinonna S, et al. Renal cell carcinoma: a study through NMR-Based metabolomics combined with transcriptomics. Diseases. 2016;4(1):7. doi: 10.3390/diseases4010007
   PubMedGoogle Scholar
• Qi X, Li Q, Che X, et al. The uniqueness of clear cell renal cell carcinoma: summary of the process and abnormality of glucose metabolism and lipid metabolism in ccRCC. Front Oncol. 2021;11:727778. doi: 10.3389/fonc.2021.727778
   PubMed Web of Science ®Google Scholar
• Reinfeld BI, Madden MZ, Wolf MM, et al. Cell-programmed nutrient partitioning in the tumour microenvironment. Nature. 2021;593(7858):282–288. doi: 10.1038/s41586-021-03442-1
   PubMed Web of Science ®Google Scholar
• Guo Z, Li Y, Zhang D, et al. Axl inhibition induces the antitumor immune response which can be further potentiated by PD-1 blockade in the mouse cancer models. Oncotarget. 2017;8(52):89761–89774. doi: 10.18632/oncotarget.21125
   PubMedGoogle Scholar
• Afzal MZ, Mercado RR, Shirai K. Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma. Journal For ImmunoTherapy Of Cancer. 2018;6(1):64. doi: 10.1186/s40425-018-0375-1
   PubMedGoogle Scholar
• Dang W, Xiao J, Ma Q, et al. Combination of p38 MAPK inhibitor with PD-L1 antibody effectively prolongs survivals of temozolomide-resistant glioma-bearing mice via reduction of infiltrating glioma-associated macrophages and PD-L1 expression on resident glioma-associated microglia. Brain Tumor Pathol. 2021;38(3):189–200. doi: 10.1007/s10014-021-00404-3
   PubMed Web of Science ®Google Scholar
• Grossi V, Lucarelli G, Forte G, et al. Loss of STK11 expression is an early event in prostate carcinogenesis and predicts therapeutic response to targeted therapy against MAPK/p38. Autophagy. 2015;11(11):2102–2113. doi: 10.1080/15548627.2015.1091910
   PubMed Web of Science ®Google Scholar
• Madiraju AK, Erion DM, Rahimi Y, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature. 2014;510(7506):542–546. doi: 10.1038/nature13270
   PubMed Web of Science ®Google Scholar
• Liu J, Li M, Song B, et al. Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft. Urol Oncol. 2013;31(2):264–270. doi: 10.1016/j.urolonc.2011.01.003
   PubMed Web of Science ®Google Scholar
• Zhou X, Chen J, Yi G, et al. Metformin suppresses hypoxia-induced stabilization of HIF-1α through reprogramming of oxygen metabolism in hepatocellular carcinoma. Oncotarget. 2016;7(1):873–884. doi: 10.18632/oncotarget.6418
   PubMedGoogle Scholar